2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

5876 Membrane-bound IL15-IL15Rα complex enhances the efficacy and persistence of CD19 and CD22 CAR-T cells in R/R lymphoma

Xingcheng Yang, Chenchen Gu2, Bofeng Liu3, Jinyuan Ho4, Jingyi Yin5, Yue Wang6, Shiqi Huang7, Jia Wei, MD, PhD8
1 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
2 Key Laboratory of Molecular Medicine and Biological Diagnosis and Treatment (Ministry of Industry and Information Technology), School of Life Science, Beijing Institute of Technology, Beijing, China
3 Key Laboratory of Molecular Medicine and Biological Diagnosis and Treatment (Ministry of Industry and Information Technology), School of Life Science, Beijing Institute of Technology, Beijing, China
4 Academy of Pharmacy, Xi’an Jiaotong-Liverpool University, Suzhou, China
5 Academy of Pharmacy, Xi’an Jiaotong-Liverpool University, Suzhou, China
6 Academy of Pharmacy, Xi’an Jiaotong-Liverpool University, Suzhou, China
7 Academy of Pharmacy, Xi’an Jiaotong-Liverpool University, Suzhou, China
8 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China

Background: Chimeric antigen receptor (CAR) T-cell therapy is a treatment modality for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). However, long-term disease control is limited by T-cell exhaustion within the tumor microenvironment (TME) and tumor relapse associated with antigen escape. Interleukin-15 (IL-15) is involved in T-cell survival and memory phenotype formation. We hypothesized that engineering CAR-T cells to co-express a membrane-bound IL15-IL15Rα complex would provide localized survival signaling to mitigate exhaustion. Furthermore, we postulated that sequential infusion of CD19- and CD22-targeted IL15-IL15Rα CAR-T cells would address tumor antigen escape.

Methods: Lentiviral vectors encoding CD19 or CD22 CARs co-expressed with an IL15-IL15Rα complex via a T2A sequence (CAR-CD19-IL15RF-T and CAR-CD22-IL15RF-T) were constructed. In vitro, T-cell memory phenotype (CD62L+) and cytotoxicity against CD19+ and CD22+ lymphoma cell lines were evaluated. Downstream signaling mechanisms were analyzed via RNA sequencing (RNA-seq) and Western blot. In vivo efficacy and safety were assessed in a systemic Raji-luciferase NSG mouse model. Mice received single or sequential infusions of conventional or IL15-IL15Rα-armed CAR-T cells. Primary endpoints included tumor burden, OS, in vivo CAR-T proliferation, phenotypic evolution, and systemic cytokine profiles.

Results: Flow cytometry and Western blot confirmed surface expression of the IL15-IL15Rα complex. In vitro, the IL15-IL15Rα CAR-T cells maintained a higher proportion of CD62L+ central memory T cells during expansion and exhibited increased cytotoxicity at low E:T ratios compared to conventional CAR-T cells. RNA-seq indicated transcriptomic alterations, including the upregulation of genes associated with cell survival, metabolism, and the JAK-STAT pathway, which was supported by elevated phosphorylation of JAK3 and STAT5 on Western blot. In vivo, IL15-IL15Ra-armed CAR-T cells exhibited cell expansion and persistence. Peripheral blood flow cytometry showed an increased proportion of central memory T cells (CD8+CAR+CD45RA-CCR7-) and a lower frequency of exhausted T cells (CD8+CAR+PD-1+). Mice receiving the sequential infusion of CAR-CD19-IL15RF-T followed by CAR-CD22-IL15RF-T achieved tumor clearance and a 100% overall survival rate at the observed endpoint, compared to the PBS control cohort which succumbed by Day 21. Systemic levels of pro-inflammatory cytokines (IL-6, TNF-α, and IFN-γ) remained at baseline. Liver histopathology showed an absence of tumor infiltration and tissue necrosis, with mild T-cell infiltration.

Conclusions: The integration of a membrane-bound IL15-IL15Rα complex supports CAR-T cell antitumor activity, persistence, and central memory maintenance through activation of the JAK3/STAT5 pathway. The sequential targeting of CD19 and CD22 with IL15RF-armed CAR-T cells leads to tumor clearance in vivo without elevated systemic cytokines. This strategy addresses T-cell exhaustion and antigen escape, providing a potential approach for the treatment of R/R lymphoma.

Xingcheng Yang: No relevant conflicts of interest to declare.